Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: A phase II study

Journal of B.U.ON.

Volumn 10, Issue 2, 2005, Pages 201-204

  Fried, G ^a,b   Stein, Moshe E ^a   Kuten, A ^a   Quigley, M ^c   Gershuny, A ^c   Siegelmann Danieli, N ^a,d   Zaidan, J ^e   Haim, N ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Poriya Hospital   (Israel)

^c OLDCHURCH HOSPITAL   (United Kingdom)

^d GEISINGER MEDICAL CENTER   (United States)

^e Rebecca Sieff Government Hospital   (Israel)

Author keywords

Chemotherapy; Etoposide; Metastatic breast cancer; Phase II study; Vinorelbine

Indexed keywords

ANALGESIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; STEROID; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; STOMATITIS; TREATMENT OUTCOME;

EID: 24944487076     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40.
2. Ibrahim NK, Rahman Z, Valero V et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast cancer. Cancer 1999; 86: 1251-1257.
3. Gebbia V, Mauceri G, Fallica G et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma: A phase I-II clinical investigation. Oncology 2002; 63: 23-30.
4. Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol 2002; 13: 1730-1736.
5. Lokich JJ, Anderson N, Bern M, Coco F, Dow E. The multi-fractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: A phase I-II study of paclitaxel, cisplatin and vinorelbine. Cancer 1999; 85: 499-503.
6. Fried G, Stein ME, Haim N. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study. Med Ped Oncol 2000; 34: 10-13.
7. Cocconi G, Tonato M, Di Costanzo F et al. Platinum and etoposide in chemotherapy for refractory metastatic breast cancer: A phase II trial of the Italian Oncology Group for Clinical Research. Eur J Cancer 1986; 22: 761-764.
8. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
9. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Semin Oncol 2003; 30 (Suppl 3): 6-10.
10. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refratory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-1400.
11. Degardin M, Bonneterre J, Hecquet B et al. Vinorelbine as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 424-426.
12. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: A phase II study. Cancer Chemother Pharmacol 1996; 39: 150-156.
13. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999; 22: 298-302.
14. Gurel N, Akali Z, Yanna D. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000; 86: 283-285.
15. Ray-Coquard I, Biron P, Bachelot T et al. Vinorelbine and cisplatin [CIVIC regimen] for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998; 8: 134-140.